drugset / Trial / NCT00615810
ROCKET I - Randomized Open Label Switch for Cholesterol Elevation on Kivexa Evaluation Trial
RandomizedParallel-groupOpen-labelTreatment
Summary
This study aims to investigate whether patients switching their backbone from Kivexa to Truvada, who already have raised total cholesterol prior to switching, have an improvement in their total cholesterol after 12 weeks of treatment. If an improvement is demonstrated the study aims to show whether this has a beneficial effect on the patient's overall cardiovascular risk and long term prognosis.
Timeline
- Start
- 2008-03
- Primary completion
- 2009-10
- Completion
- 2010-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Atripla | Unknown | 200 mg | Oral |
| Subject | Atripla | Unknown | 300 mg | Oral |
| Subject | Atripla | Unknown | 600 mg | Oral |
| Comparator | Efavirenz | Other / unclassified | 600 mg | Oral |
| Comparator | Raltegravir | Other / unclassified | 300 mg | Oral |
| Comparator | Raltegravir | Other / unclassified | 600 mg | Oral |